Sands Capital Management
TARS icon

Sands Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Sands Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-260,000
Closed -$7.54M – 75
2021
Q2 		$7.54M Hold
260,000
– – 0.01% 77
2021
Q1 		$8.38M Hold
260,000
– – 0.02% 74
2020
Q4 		$10.7M Buy
+260,000
New +$7.41M 0.02% 76

Other funds holding TARS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Sands Capital Management's TARS Position: Q3 2021 in Review

Sands Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2021, closing a stake of 260,000 shares — an estimated $7.54M sold.

Sands Capital Management first reported a position in TARS in Q4 2020 and held it in 3 quarters. The position peaked at $10.7M in Q4 2020. 44 funds tracked by Wall St. Rank hold TARS as of Q3 2021.

  • Sands Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sands Capital Management sold 260,000 Tarsus Pharmaceuticals shares in Q3 2021, an estimated $7.54M.
  • Sands Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Sands Capital Management's Tarsus Pharmaceuticals position peaked at $10.7M in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2021.

Based on Sands Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.